Aktie A3C8U3 ALLARITY THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Allarity Therapeutics, Inc. Nasdaq Stockholm

Aktien

A3C8U3

US0167441049

ALLR

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Top Premarket Gainers
Top Premarket Gainers
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A403V9 Aktie
  4. A3C8U3 Aktie
  5. Nachrichten Allarity Therapeutics, Inc.
  6. Andere Sprachen